Pancreatic adenocarcinoma remains a devastating disease with a 5-year survival rate not
exceeding 6%. Treatment of this disease remains a major challenge. This article reviews the …

Background Pancreatic cancer (PC) is a highly lethal disease with few effective treatment
options. Over the past few decades, many anti‐cancer therapies have been tested in the …

Pancreatic cancer is the fourth leading cause of cancer-related death among men and
women in the United States. A major challenge in treatment remains patients' advanced …

Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-
quality multiphase imaging can help to preoperatively distinguish between patients eligible …

Simple Summary This review article presents a synopsis of the key clinical developments,
their limitations, and future perspectives in the treatment of pancreatic cancer. In the first part …

Background We systematically reviewed and performed a meta-analysis of the available
data regarding neoadjuvant chemo-and/or radiotherapy with special emphasis on tumor …

Fluorouracil (5-FU) alone or in combination with other therapeutic drugs has been widely
used for clinical treatment of various cancers. However, 5-FU-based chemotherapy has …

Background Locoregional pancreatic ductal adenocarcinoma (PDAC) may progress rapidly
and/or disseminate despite having an early stage at diagnostic imaging. A prolonged …

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths in
the US, and it is expected to be the second leading cause of cancer deaths by 2030. The …

Familiäres Pankreaskarzinom (S. e836): Hier wird erstmals definiert, welchen Angehörigen
von Patienten mit familiärem Pankreaskarzinom welche genetischen Untersuchungen zur …